Harvest One Cannabis Logo
Harvest One logo
toggle menu

Harvest One announces strategic collaboration agreement with eSense-Lab Limited

November 14, 2017

Harvest One Cannabis Inc. (TSXV:HVST) ("Harvest One") is pleased to announce that they have entered into a strategic collaboration agreement (the "Agreement") with an Australian-based life sciences company eSense-Lab Limited ("eSense" or "ESE") (ASX: ESE), with Harvest One providing technical expertise and its access to global networks. For more information on the Agreement please reference MMJ Phytotech’s press release dated November 14th, 2017

About eSense-Lab Ltd (ASX: ESE).

eSense-Lab Ltd is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare of high value plants.

ESE can then use this model to ‘reverse engineer’ a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant’s health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost. To learn more about eSense-Lab please visit www.esense-lab.com  

About Harvest One Cannabis Inc. (TSX.V: HVST)

Harvest One controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation and sales license, making Harvest One one of only a few companies globally with the capacity to commercially cultivate and sell cannabis in a federally regulated environment.

For more information about Harvest One, please contact:

Colin Clancy
Investor Relations
+ 1 (877) 915 7934
cclancy@mmj.ca

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the PCT application. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Email Signup